The consolidated revenue forecast for the fiscal year ending December 2026 is 27.158 billion yen, expected to increase approximately 1.2% compared to the previous fiscal year, while profit items remain undisclosed due to significant uncertainties.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/2160-20260331-02.pdf","jir_short_summary":"The consolidated revenue forecast for the fiscal year ending December 2026 is 27.158 billion yen, expected to increase approximately 1.2% compared to the previous fiscal year, while profit items remain undisclosed due to significant uncertainties.","jir_summary":"### Summary of Earnings Guidance\nGNI Group, Inc. disclosed the consolidated revenue forecast for the fiscal year ending December 2026 as 27.158 billion yen, which was previously undecided. This represents an approximate 1.2% increase from the previous fiscal year\u2019s revenue of 26.840 billion yen. However, profit-related items such as operating income and beyond remain undisclosed due to multiple uncertainties including the progress of R&D expenses, timing of regulatory approvals, upfront investments related to new drug approvals, strategic investments in the medtech business, and accounting factors associated with M&A.\n\n### Outlook and Policy\nHaving experienced downward revisions of earnings guidance in the past two periods due to delays in regulatory approvals, the company aims to avoid causing investor confusion by excluding uncertain estimates based on regulatory approvals and will continue to withhold disclosure of profit items until a reasonable calculation is possible. The company plans to carefully monitor business trends and promptly disclose rational earnings guidance including profit items once feasible.","jir_financial_highlights":"Revenue: 27,158 million yen (YoY +1.2%)\nOperating Income: Undisclosed (Unknown)\nIncome Before Tax: Undisclosed (Unknown)\nNet Income: Undisclosed (Unknown)\nNet Income Attributable to Owners of Parent: Undisclosed (Unknown)","jir_category":"","jir_hashtags":"#GNIGroupInc, #EarningsGuidance, #JapaneseStocks","jir_key_figures":"Revenue Forecast: 27,158 million yen (Fiscal Year Ending December 2026)\nPrevious Fiscal Year Revenue: 26,840 million yen (Fiscal Year Ending December 2025)\nExchange Rates: USD\/JPY=155.0, CNY\/JPY=21.0 (As of March 31, 2026)","jir_meta_title":"GNI Group, Inc. Forecasts 27 Billion Yen Revenue for Fiscal Year Ending December 2026; Profit Items Undisclosed","jir_meta_description":"GNI Group, Inc. projects consolidated revenue of 27.158 billion yen for the fiscal year ending December 2026. Profit items remain undisclosed due to uncertainties in R&D expenses and regulatory approvals, with disclosure planned once reasonable calculations are possible.","jir_og_title":"GNI Group Discloses Revenue Forecast for Fiscal Year Ending December 2026","jir_og_description":"Announced revenue forecast of 27.158 billion yen for fiscal year ending December 2026. Profit items are undecided and remain undisclosed. Plans to disclose reasonable forecasts after carefully monitoring business progress.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2023\\\",\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\",\\\"Fiscal Year Ending December 2026 (Forecast)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[26010,23611,26840,27158],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Trends (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2023\\\",\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\",\\\"Fiscal Year Ending December 2026 (Forecast)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Pharmaceuticals\\\",\\\"data\\\":[15742,15847,17314,16000],\\\"backgroundColor\\\":\\\"#8e5ea2\\\"},{\\\"label\\\":\\\"Drug Discovery\\\",\\\"data\\\":[5805,1439,789,544],\\\"backgroundColor\\\":\\\"#3cba9f\\\"},{\\\"label\\\":\\\"MedTech\\\",\\\"data\\\":[2841,5189,7584,9674],\\\"backgroundColor\\\":\\\"#e8c3b9\\\"},{\\\"label\\\":\\\"Others\\\",\\\"data\\\":[1623,1156,1169,940],\\\"backgroundColor\\\":\\\"#c45850\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income (Loss) Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2023\\\",\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (Loss)\\\",\\\"data\\\":[13108,1402,-3471],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-38313","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n